Medtronic plc (MDT)
| Market Cap | 100.34B -5.9% |
| Revenue (ttm) | 35.48B +6.9% |
| Net Income | 4.61B +8.3% |
| EPS | 3.58 +9.5% |
| Shares Out | 1.28B |
| PE Ratio | 21.83 |
| Forward PE | 13.37 |
| Dividend | $2.84 (3.63%) |
| Ex-Dividend Date | Mar 27, 2026 |
| Volume | 9,226,014 |
| Open | 77.49 |
| Previous Close | 78.15 |
| Day's Range | 76.98 - 78.17 |
| 52-Week Range | 74.40 - 106.33 |
| Beta | 0.63 |
| Analysts | Buy |
| Price Target | 107.08 (+38.2%) |
| Earnings Date | Jun 3, 2026 |
About MDT
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair produc... [Read more]
Financial Performance
In fiscal year 2025, Medtronic's revenue was $33.54 billion, an increase of 3.62% compared to the previous year's $32.36 billion. Earnings were $4.66 billion, an increase of 26.82%.
Financial StatementsAnalyst Summary
According to 31 analysts, the average rating for MDT stock is "Buy." The 12-month stock price target is $107.08, which is an increase of 38.20% from the latest price.
News
Medtronic reinstated with a Neutral at Goldman Sachs
Goldman Sachs reinstated coverage of Medtronic (MDT) with a Neutral rating and $84 price target which offers 7.5% upside potential. The shares at current levels offer a balanced risk/reward, trading…
Medtronic plans to buy SPR Therapeutics for $650 million to expand pain treatment options
Medical device maker Medtronic said on Wednesday it plans to acquire privately held SPR Therapeutics for about $650 million in cash, expanding its portfolio of treatments for chronic pain.
Medtronic announces intent to acquire SPR Therapeutics for $650M
Medtronic (MDT) announced its intent to acquire SPR Therapeutics, a privately held medical technology company and a recognized leader in temporary, percutaneous peripheral nerve stimulation, or PNS, t...
Medtronic announces intent to acquire SPR Therapeutics, Inc., expanding care options for people living with chronic pain
Acquisition will enhance Medtronic's Neuromodulation portfolio with temporary peripheral nerve stimulation (PNS) technology, enabling earlier intervention for chronic pain sufferers GALWAY, Ireland, M...
Orchestra BioMed Receives $20 Million Payment from Medtronic Under Previously Announced Financing Agreement
Payment fulfills previously disclosed funding commitment of $20 million and supports planned completion of the BACKBEAT Global Pivotal Trial (“BACKBEAT Trial”) evaluating Atrioventricular Interval Mod...
FDA Grants Orchestra BioMed Additional Breakthrough Device Designation for AVIM Therapy
Atrioventricular Interval Modulation (“AVIM”) Therapy Food and Drug Administration (“FDA”) Breakthrough Device Designations span the broader population of patients with uncontrolled hypertension despi...
Medtronic receives CE mark for Stealth AXiS surgical system
Medtronic (MDT) has received CE mark for the Stealth AXiS surgical system. The Stealth AXiS system is indicated for spine and cranial procedures.
Medtronic announces CE Mark for Stealth AXiS™ surgical system
Following recent FDA clearances, Medtronic is accelerating access to integrated planning, navigation, and robotics platform across Europe GALWAY, Ireland, April 28, 2026 /PRNewswire/ -- Medtronic, a g...
Medtronic says cyberattack on IT network has not disrupted operations
Medical device maker Medtronic said on Monday a cyberattack on its computer systems last week did not affect its products or ability to meet patient needs, and is not expected to materially impact i...
Medtronic announces milestones for Sphere-9, Sphere 360 catheters
Medtronic (MDT) announced continued momentum for the Affera family of technologies for cardiac arrhythmia treatment, including promising data presented at the Heart Rhythm Society, HRS, Annual Meeting...
Medtronic announces FDA granted Breakthrough Device Designations to Sphere-9
Medtronic (MDT) announced the U.S. Food and Drug Administration granted Breakthrough Device Designation for the Sphere-9 catheter for the treatment of VT, providing an expedited regulatory pathway for...
Medtronic announces key Affera™ clinical study milestones for Sphere-9™ and Sphere-360™ catheters as global adoption continues
HRS late-breaking data: Interim results highlight six-month outcomes for patients treated with the Sphere-9 catheter for sustained monomorphic ventricular tachycardia (VT) Breakthrough device designat...
Medtronic price target lowered to $95 from $108 at Jefferies
Jefferies analyst Matthew Taylor lowered the firm’s price target on Medtronic (MDT) to $95 from $108 and keeps a Hold rating on the shares. The firm updated its FY26 EPS…
Medtronic price target lowered to $90 from $104 at UBS
UBS lowered the firm’s price target on Medtronic (MDT) to $90 from $104 and keeps a Neutral rating on the shares. The firm updated its model to reflect the diabetes…
Medtronic completes acquisition of CathWorks, expanding its leadership in transforming care for patients with cardiovascular disease
CathWorks FFRangio® System employs drug-free, wire-free technology for comprehensive physiological assessment GALWAY, Ireland, April 20, 2026 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader ...
Medtronic price target lowered to $95 from $103 at Truist
Truist analyst Richard Newitter lowered the firm’s price target on Medtronic (MDT) to $95 from $103 and keeps a Hold rating on the shares as part of a broader research…
Medtronic price target lowered to $120 from $125 at Mizuho
Mizuho lowered the firm’s price target on Medtronic (MDT) to $120 from $125 and keeps an Outperform rating on the shares. The firm adjusted estimates and price targets for several…
Medtronic to announce financial results for its fourth quarter and full fiscal year 2026
GALWAY, Ireland, April 13, 2026 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that it will report financial results on Wednesday, June 3, 2026, f...
Medtronic price target lowered to $106 from $108 at Evercore ISI
Evercore ISI analyst Vijay Kumar lowered the firm’s price target on Medtronic (MDT) to $106 from $108 and keeps an Outperform rating on the shares.
GE HealthCare announces digital integration between bkActiv™ intraoperative ultrasound system and Medtronic Stealth AXiS™ surgical navigation system
CHICAGO--(BUSINESS WIRE)--GE HealthCare today announced a digital integration between the GE HealthCare bkActiv™ intraoperative ultrasound (iUS) system and the Medtronic Stealth AXiS™ surgical navigat...
Medtronic price target lowered to $110 from $117 at Citi
Citi analyst Joanne Wuensch lowered the firm’s price target on Medtronic (MDT) to $110 from $117 and keeps a Buy rating on the shares. The firm adjusted targets in the…
Medtronic price target lowered to $95 from $105 at Stifel
Stifel lowered the firm’s price target on Medtronic (MDT) to $95 from $105 and keeps a Hold rating on the shares. The firm is updating its model to incorporate expected…
Medtronic price target lowered to $115 from $125 at Argus
Argus analyst David Toung lowered the firm’s price target on Medtronic (MDT) to $115 from $125 and keeps a Buy rating on the shares. The management’s move to restructure the…
Medtronic gets US FDA nod to use surgical system in cranial, ENT surgeries
Medtronic said on Friday the U.S. Food and Drug Administration has cleared its surgical system for use in cranial and ear, nose and throat procedures, expanding the platform beyond the sp...